The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
Open accessAbstract
Two selective estrogen receptor modulators, tamoxifen and raloxifene, have been shown in randomized clinical trials to reduce the risk of developing primary invasive breast cancer in high-risk women. In 1998, the U.S. Food and Drug Administration (FDA) used these studies as a basis for approving tamoxifen for primary breast chemoprevention in both premenopausal and postmenopausal women at high risk. In 2007, the FDA approved raloxifene for primary breast cancer chemoprevention for postmenopausal women. Data from the year 2010 National Health Interview Survey were analyzed to estimate the prevalence of tamoxifen and raloxifene use for chemoprevention of primary breast cancers among U.S. women. Prevalence of use of chemopreventive agents for primary tumors was 20,598 (95 % CI, 518–114,864) for U.S. women aged 35–79 for tamoxifen. Prevalence was 96,890 (95 % CI, 41,277–192,391) for U.S. women aged 50–79 for raloxifene. Use of tamoxifen and raloxifene for prevention of primary breast cancers continues to be low. In 2010, women reporting medication use for breast cancer chemoprevention were primarily using the more recently FDA approved drug raloxifene. Multiple possible explanations for the low use exist, including lack of awareness and/or concern about side effects among primary care physicians and patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., McTiernan, A., Robbins, J., Johnson, K. C., Martin, L. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103507 · Cited by 970
Cited by
Breast cancer statistics, 2013
DeSantis, C., Ma, J., Bryan, L., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21203 · Cited by 2,143
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Atypical Hyperplasia of the Breast — Risk Assessment and Management Options
Hartmann, L. C., Degnim, A. C., Santen, R. J., Dupont, W. D., & Ghosh, K. (2015) · New England Journal of Medicine · doi:10.1056/nejmsr1407164 · Cited by 366
Visvanathan, K., Hurley, P., Bantug, E., Brown, P., Col, N. F., Cuzick, J., Davidson, N. E., DeCensi, A., Fabian, C., Ford, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3122 · Cited by 307
Priorities for the primary prevention of breast cancer
Colditz, G. A., & Bohlke, K. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21225 · Cited by 277
Metadata
- Authors
- Waters, E. A., McNeel, T. S., Stevens, W. M., & Freedman, A. N.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2012-05-24
- Volume
- 134
- Issue
- 2
- Pages
- 875-880
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2070541537
- Cited by
- 181
- References
- 1
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. https://app.cochat.ai/papers/10.1007/s10549-012-2089-2
- The paper
- Waters, E. A., McNeel, T. S., Stevens, W. M., & Freedman, A. N. (2012). Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-012-2089-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.